Cosciens Biopharma (CSCI) said Thursday it has started the phase 2a clinical efficacy study of its avenanthramides product, which it is developing for potential applications in managing conditions related to inflammation.
In phase 2a of the study, 20 patients with mild to moderate inflammation will participate. This phase is designed to assess potential efficacy in two arms with patients receiving selected doses of 480 mg and 960 mg per day, the company said. Initial dosing is expected to occur on March 14.
The Data Safety and Monitoring Board recommended initiating phase 2a after phase 1, done in November 2023, showed the favorable safety profile of the product, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.